Roche launches CE-marked Cobas PIK3CA Mutation Test

Create PDF

Dec. 15, 2020—Roche launched the Cobas PIK3CA Mutation Test CE-IVD for patients with advanced or metastatic breast cancer in countries accepting the CE mark. The test was previously available for research use only.